Most of the writing about skin boosters is about who benefits. The more useful clinical question — and the one that protects your outcomes, your reviews and your chair time — is who should not get a skin booster. Negative selection is a skill. It is also the part of the consultation most injectors have never been taught to do out loud.
The short version: a skin booster acts on the quality and hydration of a dermis that still works. It does not act on elastic recoil, it does not reposition descended tissue, and it cannot produce a change large enough to be visible on a face whose dominant finding is laxity. Offering it anyway is not a small error. You will take the patient's money, deliver a result neither of you can see, and lose them — usually to someone who told them the truth.
The laxity threshold
The ideal skin booster patient has early crepiness. Fine surface change, dullness, a dermis that has thinned a little but has not given up. Pinch that skin and it comes back promptly.
The poor candidate has laxity. Real, established, visible laxity — the skin at the lateral cheek and along the jawline has lost its recoil and now hangs. Pinch it and it returns slowly, or stays tented for a moment before it settles.
That pinch-and-release test takes seconds and it is the most decision-relevant thing in the whole examination. It is also the test most often skipped, because a busy consultation defaults to looking rather than touching, and laxity is easy to miss on a face lit from above.
Why does the distinction matter so much? Because of magnitude. A skin booster produces an incremental improvement in dermal hydration and surface quality. That improvement is real, and against a background of early textural change it is clearly visible. Against a background of significant laxity, it is a rounding error. The patient will look at the before-and-after and see nothing, because the thing they are unhappy about was never being treated.
This is what I mean when I say that selecting the right patient to deliver the right treatment is a must. It is not a customer-service principle. It is the mechanism by which the treatment works or does not.
The other patients to decline
Laxity is the headline, but it is not the only branch that ends in "not this, not today."
The patient whose real complaint is descent, not quality. Listen to the words. "Everything has come down." "I want it lifted." "It used to sit here." Those are positional complaints. No intradermal hydration product addresses position. If you hear a positional complaint and answer it with a quality treatment, you have agreed to be judged on a result you did not attempt.
The patient whose lines are dynamic. A line that appears only with expression is a muscular problem. Injecting the dermis to treat it will not work, and the patient will conclude that skin boosters do not work, which is the wrong lesson learned at your expense.
The patient with active inflammation or infection in the field. Defer until it has resolved. This is standard across injectables and it is not negotiable because the treatment is elective.
The reactive or pigment-prone patient, as a relative caution. Delivery across a field means repeated dermal puncture, which in reactive phenotypes can mean prolonged erythema and post-inflammatory hyperpigmentation. A 2026 commentary in the Journal of Cosmetic Dermatology sets out why: the dense innervation, microvasculature and immune activity of the dermis make it a reactive tissue to treat (Lim TS, Lee S, Haykal D, Yi KH. J Cosmet Dermatol. 2026;25:e70906. doi:10.1111/jocd.70906). In these patients plan for fewer passes, smaller aliquots and a more conservative field, and set the recovery expectation accordingly.
The patient mid-course on rapid weight loss. A face that is still changing is a face you cannot plan against. This is not an absolute contraindication and quality work is often the safest thing to offer that population, but committing a full plan to a moving baseline is a decision to redo it later.
The patient who has already been over-treated. If the face in front of you is heavy with previous product, adding anything is the wrong instinct even when the skin genuinely is dry. Deal with what is there first.
The patient whose expectations you cannot move. If, after a clear explanation, the patient still believes a booster will lift their jawline, the problem is not the product. Treating anyway converts a disagreement into a complaint.
Do not over-promise what you cannot deliver
The limitation statement I give every biostimulator and booster patient has three parts, and I say all three before anyone commits to anything.
First: swelling and bruising are part of this. Not a complication, not bad luck — an expected consequence of putting a needle through a dermis multiple times. Build it into the scheduling conversation.
Second: this does not add volume. Biostimulators and boosters work on skin quality and tightening. If the patient's mental image of the result involves fullness, that image came from a filler photograph and needs to be corrected now.
Third: this does not replace surgery. That sentence, in those words, is the one that saves you. It is honest, it is unambiguous, and once you have said it the patient cannot later claim they expected a facelift result from an injection.
Over-promising is the most expensive thing you can do in this specialty, because you cannot un-promise it. The patient will measure the outcome against whatever you set at consultation, and you own the setting.
How to have the referral conversation
Declining a treatment feels like losing a patient. Done properly, it is the opposite — and it is worth understanding why the surgical referral is not the exit door you think it is.
Injectable practice and surgical practice are not sequential and mutually exclusive. A 2026 retrospective chart review in the Journal of Cosmetic Dermatology looked at patients who underwent facelift surgery and had a documented history of injectable treatment: all had received neurotoxin before surgery, 90% had received hyaluronic acid filler and 55% had received poly-L-lactic acid or calcium hydroxylapatite. After surgery, all resumed neurotoxin and 60% received filler within the first post-operative year (Myers B, Firsowicz M, Kamrani P, Dayan S, Fabi S. J Cosmet Dermatol. 2026;25:e70690. doi:10.1111/jocd.70690). The cohort was small and the design retrospective, so treat it as descriptive rather than definitive — but the pattern it describes matches practice. Surgical patients are injectable patients. They were before, and they are after.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Aesthetic & Injectable Training courses — live patients, expert faculty, and ongoing mentorship.
Referring appropriately is how you become the clinician who is right about things.
The structure that works
Name the finding, in plain language and without judgement. "What's bothering you here isn't the surface of the skin. The skin has lost some of its elasticity, so it's sitting differently than it used to." You are describing tissue, not criticising a face.
Say what the treatment you have would and would not do. "A booster would improve the texture and the hydration. It would not change where the skin sits. Given what I'm seeing, I don't think you'd be able to tell the difference in a photograph, and I don't want to take your money for something you can't see."
Offer the honest alternatives, including the surgical one. Energy-based tightening. Thread-based repositioning where the anatomy supports it — Empire covers the realistic durability question in how long a thread lift lasts and the specific lower-face application in thread lift for a double chin. A staged combination plan with modest, stated expectations. Or a consultation with a surgeon.
Keep the door open explicitly. "If you decide to have surgery, come back afterwards — skin quality work is genuinely valuable on a face that's been lifted, and most of my surgical patients keep up their injectables." That single sentence turns a decline into a relationship.
Offer something you can stand behind today, if there is one. Often there is: quality work at a modest scale, a skincare plan, a treatment for a secondary finding you can actually move. What you must not do is substitute a treatment you do not believe in because the patient came in expecting to spend money.
Document it. Record the finding, the recommendation, the alternatives offered and the patient's decision. A declined treatment is a clinical decision and it belongs in the notes like any other.
What "realistic" sounds like at the chairside
Realistic is not pessimistic. It is specific.
Vague: "You'll see some improvement over time." Specific: "Over the next three months you should see the texture here become smoother and the skin hold light better. The line that runs from here to here is structural — that one will not change. If you want that addressed, it needs a different plan."
Vague: "Most people are happy with it." Specific: "You will swell on the day and it will look better than the end result for about forty-eight hours. Then it will go back to where you started and stay there for a few weeks before anything real happens. That is the normal course, not a problem."
The specificity is what makes the promise keepable, and a keepable promise is the only kind worth making. It also does something useful to your own practice: naming the exact change you expect forces you to decide whether you actually expect it.
These assessment findings and consultation approaches reflect Maritza Mejia's clinical practice as taught in Empire Medical Training's hands-on curriculum. Technique is learned under supervision; this article is educational and is not a substitute for training.
The practice consequence
An injector who never declines anything develops a predictable problem: a portfolio of underwhelming results in patients who were never going to respond, and a reputation built on the patients who happened to be good candidates by accident.
Negative selection fixes that. It also, over time, changes the kind of patient who comes to you — because the patient you turned away honestly tells people about it, and so does the patient whose result worked because you picked them correctly.
If the gap in your practice is the range of tools to offer rather than the judgement to choose between them, Empire's Facial Contouring Injectables workshop covering Sculptra, Radiesse, exosomes and PDRN builds the biostimulator side, Advanced PDO Thread Lift Training covers the repositioning option, and Complete Cosmetic Laser Training addresses the energy-based alternatives you will want to be able to offer the laxity patient.
Frequently Asked Questions
How much laxity is too much for a skin booster?
Judge it by recoil rather than by appearance. If pinched skin at the lateral cheek or pre-jowl region returns promptly, quality work is worth doing. If it returns slowly or stays tented, laxity is the dominant finding and a hydration treatment will not produce a change the patient can see in a photograph.
Can I combine a skin booster with something that does treat laxity?
Yes, and that is often the right plan — provided the laxity component is doing the heavy lifting and the booster is an adjunct rather than the headline. The error is offering the booster alone and hoping. State clearly which part of the plan addresses which finding so the patient can judge the result fairly.
What do I say if the patient insists on the treatment anyway?
Restate the limitation in writing, document that you advised against it, and then decide whether you are willing to proceed. Some clinicians will, with clear consent; some will not. Either position is defensible. What is not defensible is proceeding without a documented record that the expected benefit was discussed and considered marginal.
Does referring a patient to a surgeon mean losing them?
Usually not. Published chart-review data on facelift patients shows they were heavily treated with injectables before surgery and returned to injectables afterwards — all resumed neurotoxin and most had filler within the first post-operative year. Say the door is open and mean it, and the referral becomes a reason for the patient to trust you.
Is post-inflammatory hyperpigmentation a reason to avoid boosters entirely?
Not entirely, but it should change your approach. Repeated puncture across a field is the reactive part; in pigment-prone phenotypes plan fewer passes, smaller aliquots and a more conservative field, stage the treatment across more visits, and make sure photoprotection and any pigment-directed skincare are in place before you start.
Disclaimer
This article reflects the clinical opinions and experience of Maritza Mejia, FNP, an independent faculty member contributing to Empire Medical Training's curriculum. The views expressed are the author's own and do not necessarily represent those of Empire Medical Training.
It is professional education, not medical advice, and is no substitute for hands-on training or independent clinical judgment. Licensed clinicians remain responsible for their own patient selection, technique and outcomes, for verifying current product labelling, and for practising within their scope and applicable law. Empire Medical Training accepts no liability for reliance on this content.
